Release Date: March 30, 2024
Expiration Date: March 30, 2025

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this program, faculty discuss common treatment-related adverse events (TRAEs) associated with novel CAR T-cell and bispecific antibody therapies, including CRS, ICANS, and hemophagocytic lymphohistiocytosis/macrophage-activation syndrome. Topics include diagnostic criteria for these challenging TRAEs and management strategies that can be utilized in the emergency setting to re-stabilize patients and support continued care for relapsed/refractory multiple myeloma.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including Emergency Medicine (EM) physicians, advanced practice professionals (APPs) in the EM setting and associated multidisciplinary care clinicians in the EM setting who provide care to patients with multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

1. Identify currently available and emerging classes of novel immunotherapies for relapsed or refractory multiple myeloma (RRMM), focusing on CAR T-cell therapies and bispecific antibodies (BsAbs)
2. Identify known treatment-related adverse events (TRAEs) associated with CAR T-cell therapies and BsAbs in RRMM patients which have the potential to be seen in the Emergency Department (ED)
3. Correlate the incidence and prevalence of CRS and ICANS with the impact of these MM-related TRAEs
4. Outline practical, applied strategies and available tools that may be used to guide ED clinicians in promptly recognizing and escalating care of MM treatment-related CRS and ICANS

Agenda

The Role of the ED in Treating Multiple Myeloma in the Era of Novel Immunotherapies

• Emerging Realities: Navigating the Influx of Myeloma Patients in the ED
• Reimagining Myeloma Management: Embracing the Era of CAR T-cell Therapies and Bispecific Antibodies
• Practical Field Guide: Monitoring and Managing MM-related Adverse Events in the ED
• On the Horizon: Clinical Trials in RRMM to Watch

Instructions for Participation and Credit

This activity is eligible for credit through March 30, 2025. After this date, this activity will expire and no further credit will be awarded.

1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME, CE, and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Joshua Richter, MD, FACP
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Chelsea Medical Center at Mount Sinai
New York City, New York

Dr. Joshua Richter received his medical degree from New York Medical College. He completed an internal medicine residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter served as Clinical Assistant Professor at Rutgers University, New Brunswick, New Jersey, and worked in the Division of Myeloma at the John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey. He is currently an Associate Professor of Medicine at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai and Director of Myeloma at Blavatnik Family Chelsea Medical Center at Mount Sinai in New York City.

Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals including New England Journal of Medicine, Blood, Journal of Clinical Oncology, and the British Journal of Haematology. Dr. Richter specializes in multiple myeloma as well as other plasma cell dyscrasias such as amyloidosis and Waldenstrom’s macroglobulinemia. His clinical research interests focus on multi-functional antibodies and precision medicine. 

Monica Wattana, MD, FAAEM
Associate Professor Education
University of Texas, MD Anderson Cancer Center
Houston, Texas

Monica Wattana is an Emergency Medicine trained physician who was first to complete a fellowship in Oncologic Emergency Medicine at UT MD Anderson Cancer Center. Upon fellowship completion, she stayed on as faculty and is currently an Associate Professor within the Department of Emergency Medicine. Dr. Wattana serves as the department Director of Education and Program Director for the Oncologic Emergency Medicine Fellowship. She oversees all educational initiatives including trainee clinical rotations and the Oncologic Emergency Medicine Fellowship. She also co-chairs the annual MD Anderson Oncologic Emergency Medicine Conference. She is a content expert in the area of oncologic emergency medicine education and clinical practice and has been invited as a speaker for multiple international and national medical conferences. She is also the author of the book Pocket Guide to Oncologic Emergencies.

Larysa Sanchez, MD
Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York City, New York

Dr. Larysa Sanchez received her medical degree from St. George’s University School of Medicine in St. George’s, Grenada. She completed an internal medicine residency at Rutgers New Jersey Medical School, Newark, New Jersey, and a hematology/oncology fellowship at Icahn School of Medicine at Mount Sinai in New York. Dr. Sanchez is currently an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and an Attending Physician in the Division of Hematology/Oncology, Multiple Myeloma Program at Mount Sinai Hospital in New York.

Dr. Sanchez is board certified in internal medicine, hematology, and medical oncology. She has authored or coauthored a number of scientific papers and reviews, as well as numerous poster presentations at ASH and ASCO. Her specific research interests focus on improving outcomes in older adults with multiple myeloma, in addition to early phase clinical trials and the investigation of novel therapeutic regimens in multiple myeloma. Dr. Sanchez is a principal investigator on 5 clinical trials and co-investigator on an additional 30 trials.

Accreditation

	CME CREDIT MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 24-025-181

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures

Dr. Joshua Richter, faculty for this educational activity, has relevant financial relationships to disclose related to speakers’ bureaus from Adaptive Biotechnologies, Bristol Myers Squibb Company, Janssen Pharmaceuticals, Inc., and Sanofi; and for consulting and advisory activities from AbbVie Inc., Bristol Myers Squibb, Genentech, Inc., Janssen, Karyopharm Therapeutics, Pfizer Inc., Sanofi, and Takeda Oncology.

Dr. Monica Wattana, content contributor for this educational activity, has disclosed no relevant financial relationships with any ineligible company (commercial interest).

Dr. Larysa Sanchez, content contributor for this educational activity, has relevant financial relationships to disclose related to consulting and advisory activities from Janssen Pharmaceuticals, Inc.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director; Sheri Sturgis, Strategy and Education Manager; Lillian McVey, Content Director; and Jennifer Murphy, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

©2024 MediCom Worldwide, Inc., 4607 Library Rd., Ste 220 #2001 · Bethel Park, PA, 15102, 267-716-5451
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.